The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $32.92 in the prior trading day, Procept BioRobotics Corp (NASDAQ: PRCT) closed at $33.0, up 0.24%. In other words, the price has increased by $0.24 from its previous closing price. On the day, 0.93 million shares were traded. PRCT stock price reached its highest trading level at $33.69 during the session, while it also had its lowest trading level at $32.46.
Ratios:
Our goal is to gain a better understanding of PRCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On July 09, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when MOLL FREDERIC H bought 20,000 shares for $39.26 per share. The transaction valued at 785,138 led to the insider holds 863,159 shares of the business.
Desai Antal Rohit sold 25,000 shares of PRCT for $1,597,711 on Jun 10 ’25. The Director now owns 64,363 shares after completing the transaction at $63.91 per share. On Jun 11 ’25, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 25,000 shares for $63.38 each. As a result, the insider received 1,584,525 and left with 39,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 1835986048 and an Enterprise Value of 1612636032. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.68 while its Price-to-Book (P/B) ratio in mrq is 4.75. Its current Enterprise Value per Revenue stands at 5.865 whereas that against EBITDA is -18.769.
Stock Price History:
The Beta on a monthly basis for PRCT is 1.01, which has changed by -0.54230237 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $103.81, while it has fallen to a 52-week low of $32.55. The 50-Day Moving Average of the stock is -14.63%, while the 200-Day Moving Average is calculated to be -41.31%.
Shares Statistics:
The stock has traded on average 1.19M shares per day over the past 3-months and 1129090 shares per day over the last 10 days, according to various share statistics. A total of 55.58M shares are outstanding, with a floating share count of 52.65M. Insiders hold about 5.37% of the company’s shares, while institutions hold 96.36% stake in the company. Shares short for PRCT as of 1759190400 were 8504080 with a Short Ratio of 7.14, compared to 1756425600 on 8370315. Therefore, it implies a Short% of Shares Outstanding of 8504080 and a Short% of Float of 18.110001.
Earnings Estimates
. The current rating of Procept BioRobotics Corp (PRCT) is the result of assessments by 9.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.23 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.45 and -$1.51 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$0.94, with 9.0 analysts recommending between -$0.41 and -$1.3.
Revenue Estimates
11 analysts predict $80.78M in revenue for. The current quarter. It ranges from a high estimate of $82.05M to a low estimate of $79.63M. As of. The current estimate, Procept BioRobotics Corp’s year-ago sales were $58.37MFor the next quarter, 11 analysts are estimating revenue of $96.43M. There is a high estimate of $97.37M for the next quarter, whereas the lowest estimate is $95.37M.
A total of 12 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $337.31M, while the lowest revenue estimate was $325.35M, resulting in an average revenue estimate of $326.53M. In the same quarter a year ago, actual revenue was $224.5MBased on 12 analysts’ estimates, the company’s revenue will be $426.85M in the next fiscal year. The high estimate is $433.5M and the low estimate is $416.1M.
